Levels of adherence required for virologic suppression among newer antiretroviral medications

Annals of Pharmacotherapy

Volumn 45, Issue 3, 2011, Pages 372-379

  Kobin, Allison Beth ^a   Sheth, Neha Umesh ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Adherence; AIDS; Antiretroviral; HIV; Virologic outcomes

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL ASSESSMENT; CROSS RESISTANCE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SELF REPORT; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV-1; HUMANS; MEDICATION ADHERENCE; TIME FACTORS; VIRAL LOAD;

EID: 79952634911     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P587     Document Type: Review

References (32)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
2. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9. (Pubitemid 30015725)
3. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65. DOI 10.1046/j.1525-1497.2002.11214.x (Pubitemid 35286241)
4. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active anti-retroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3. (Pubitemid 32549871)
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009;1-161. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2010 Mar 17).
7. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008;24:1263-8. DOI 10.1089/aid.2008.0141
8. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trial 2007;8:282-92. DOI 10.1310/hct0805-282 (Pubitemid 350099562)
9. Shuter J, Sarlo J, Kanmaz T, et al. HIV-infected patients receiving lopinavir-ritonavir-based antiretroviral therapy achieve high rates of virological suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8. DOI 10.1097/QAI.0b013e318050d8c2 (Pubitemid 46684437)
10. Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses as a predictor of HIV RNA replication. Clin Infect Dis 2010;50:1192-7. DOI 10.1086/651419
11. Nelson M, Girard PM, DeMasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naïve HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010;65:1505-9. DOI 10.1093/jac/dkq150
12. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-31. DOI 10.1097/01.aids. 0000199825.34241.49
13. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41. DOI 10.1086/507526 (Pubitemid 44435526)
14. Maggiolo F, Ravasio L, Ripamonti E, et al. Similar adherence rates favor different virological outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-63. DOI 10.1086/426595 (Pubitemid 40053474)
15. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-73. (Pubitemid 351650537)
16. Saberi P, Caswell N, Amodio-Groton M, Alpert P. Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression. AIDS Care 2008;20:741-5. DOI 10.1080/09540120701694006 (Pubitemid 351913399)
17. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009;48:484-8. DOI 10.1086/596482
18. Mena A, Blanco F, Cordoba M, et al. A pilot study assessing raltegravir QD versus BID in HIV patients included in a simplification trial. Presented at: 49th ICAAC. San Francisco, CA, September 12-15, 2009.
19. Honghu L, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77. (Pubitemid 32466236)
20. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 1998;32:749-54. DOI 10.1345/aph.17423 (Pubitemid 28341105)
21. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000;12:255-66. DOI 10.1080/09540120050042891
22. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2001;16:269-77. (Pubitemid 34118574)
23. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-73. DOI 10.1093/jac/dkn020 (Pubitemid 351426058)
24. Product information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb, March 2010.
25. Product information. Intelence (etravirine). Raritan, NJ: Tibotec Therapeutics, July 2010.
26. Product information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.
27. Product information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb, April 2010.
28. Product information. Isentress (raltegravir). Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., June 2010.
29. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77. (Pubitemid 32466236)
30. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. J Acquir Immune Defic Syndr 2008;48:216-9. DOI 10.1097/QAI.0b013e3181743955
31. Mannheimer S, Thackeray L, Hullsiek KH, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008;20:161-9. DOI 10.1080/09540120701534699 (Pubitemid 351651267)
32. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004;5:74-9. DOI 10.1310/JFXH-G3X2-EYM6-D6UG (Pubitemid 38697081)